First Time Loading...

Gilead Sciences Inc
NASDAQ:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
NASDAQ:GILD
Watchlist
Price: 65.42 USD 0.23% Market Closed
Updated: Apr 29, 2024

Gilead Sciences Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gilead Sciences Inc
Revenue Peer Comparison

Comparables:
ABBV
AMGN
MRNA
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.1B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
9%
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Moderna Inc
NASDAQ:MRNA
Revenue
$6.8B
CAGR 3-Years
104%
CAGR 5-Years
119%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

Gilead Sciences Inc
Revenue Breakdown

Breakdown by Geography
Gilead Sciences Inc

Total Revenue: 27.1B USD
100%
United States: 19.4B USD
71.7%
Europe: 4.3B USD
15.9%
Other International: 3.4B USD
12.4%

Breakdown by Segments
Gilead Sciences Inc

Total Revenue: 27.1B USD
100%
Products, Other Hiv: 18.2B USD
67.2%
Cell Therapy Products, Total Cell Therapy Pro...: 2.2B USD
8.3%
Veklury: 2.2B USD
8.1%
Trodelvy: 1.1B USD
3.9%
Hepatitis B Virus / Hepatitis Delta Virus Pro...: 1B USD
3.8%
Other Products, Total Other Product Sales: 859m USD
3.2%
Show More
Show Less

See Also

What is Gilead Sciences Inc's Revenue?
Revenue
27.1B USD

Based on the financial report for Dec 31, 2023, Gilead Sciences Inc's Revenue amounts to 27.1B USD.

What is Gilead Sciences Inc's Revenue growth rate?
Revenue CAGR 10Y
9%

Over the last year, the Revenue growth was -1%. The average annual Revenue growth rates for Gilead Sciences Inc have been 3% over the past three years , 4% over the past five years , and 9% over the past ten years .